Company news

Viking Therapeutics, Inc. news in 2024

Viking Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

November 18, 2024

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

November 11, 2024

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

November 3, 2024

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

October 27, 2024

Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

October 22, 2024

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

October 15, 2024

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

October 8, 2024

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 23, 2024

Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024

July 16, 2024

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

June 23, 2024

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

June 3, 2024

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

April 23, 2024

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

April 16, 2024

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 25, 2024

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

March 3, 2024

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

February 27, 2024

Viking Therapeutics Announces Proposed Public Offering of Common Stock

February 26, 2024

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

February 26, 2024

Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

February 6, 2024

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

January 30, 2024

Calls in 2024